Clinical Trial Details

Overview

Research Study Summary

NSABP B-47 Phase III Randomized Study of Adjuvant Chemotherapy With Versus Without Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer

Purpose

To determine whether the addition of trastuzumab to chemotherapy (TC or AC→WP) improves invasive disease-free survival (IDFS) in women with resected node-positive or high-risk node-negative breast cancer which is reported as HER2-low by all HER2 testing performed.

Patient Inclusion Criteria:

  • Age ≥ 18 years
  • The tumor must be unilateral invasive adenocarcinoma of the breast on histologic examination
  • All of the following staging criteria (according to the 7th edition of the AJCC Cancer Staging Manual) must be met:
    1. By pathologic evaluation, primary tumor must be pT1-3
    2. By pathologic evaluation, ipsilateral nodes must be pN0, pN1 (pN1mi, pN1a, pN1b, pN1c), pN2a, pN2b, pN3a, or pN3b

  • If pN0, one of the following criteria must be met:
    1. pT2 and estrogen receptor (ER) negative and progesterone receptor (PgR) negative
    2. pT2 and ER positive (PgR status may be positive or negative) and either grade 3 histology or Oncotype DX® Recurrence Score of = 25
    3. pT3 regardless of hormone-receptor status, histologic grade, and Oncotype DX® Recurrence Score

Patient Exclusion Criteria:

  • None of the following allowed:
    1. No T4 tumors including inflammatory breast cancer
    2. No definitive clinical or radiologic evidence of metastatic disease Note: Chest imaging (mandatory for all patients) and other imaging (if required) must have been performed within 90 days prior to randomization]
    3. No synchronous or previous contralateral invasive breast cancer (patients with synchronous and/or previous contralateral DCIS or LCIS are eligible)
    4. No previous ipsilateral invasive breast cancer or ipsilateral DCIS (patients with synchronous or previous ipsilateral LCIS are eligible)

    To Learn more

    CW ID: 183096
    Date Last Changed: November 6, 2014

  • Clinical Trial Snapshot

    Phase
    3
    Gender
    Female
    Age
    18 and up
    Overall Status
    Recruiting
    Facility Type
    N/A

    Contact

    Janeen V. Bazan, RN OCN BSN CCRP, Oncology Research Nurse Program Coordinator
    Advocate Sherman Hospital
    1425 North Randall Road
    Elgin, IL 60123
    Phone: 224-783-2907
    Fax: 224-783-3071

    View Map

    Research Center Information:

    Advocate Sherman Hospital

    Volunteer for this Trial

    If you would like to learn more about participating in this research study, please email the trial contact using the form below. We value your privacy and your information will only be used by the research center to contact you regarding this study.

    DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.